Online citations, reference lists, and bibliographies.
← Back to Search

The Nasal Delivery Of Nanoencapsulated Statins – An Approach For Brain Delivery

A. Clementino, Mellissa Batger, Gabriela Garrastazu, Michele Pozzoli, E. del Favero, V. Rondelli, B. Gutfilen, Thiago Barboza, M. Sukkar, S. Souza, L. Cantu', F. Sonvico
Published 2016 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Purpose Along with their cholesterol-lowering effect, statins have shown a wide range of pleiotropic effects potentially beneficial to neurodegenerative diseases. However, such effects are extremely elusive via the conventional oral administration. The purpose of the present study was to prepare and characterize the physicochemical properties and the in vivo biodistribution of simvastatin-loaded lecithin/chitosan nanoparticles (SVT-LCNs) suitable for nasal administration in view of an improved delivery of the statins to the brain. Materials and methods Chitosan, lecithin, and different oil excipients were used to prepare nanocapsules loaded with simvastatin. Particle size distribution, surface charge, structure, simvastatin loading and release, and interaction with mucus of nanoparticles were determined. The nanoparticle nasal toxicity was evaluated in vitro using RPMI 2651 nasal cell lines. Finally, in vivo biodistribution was assessed by gamma scintigraphy via Tc99m labeling of the particles. Results Among the different types of nanoparticles produced, the SVT-LCN_MaiLab showed the most ideal physicochemical characteristics, with small diameter (200 nm), positive surface charge (+48 mV) and high encapsulation efficiency (EE; 98%). Size distribution was further confirmed by nanoparticle tracking analysis and electron microscopy. The particles showed a relatively fast release of simvastatin in vitro (35.6%±4.2% in 6 hours) in simulated nasal fluid. Blank nanoparticles did not show cytotoxicity, evidencing that the formulation is safe for nasal administration, while cytotoxicity of simvastatin-loaded nanoparticles (IC50) was found to be three times lower than the drug solution (9.92 vs 3.50 μM). In rats, a significantly higher radioactivity was evidenced in the brain after nasal delivery of simvastatin-loaded nanoparticles in comparison to the administration of a similar dose of simvastatin suspension. Conclusion The SVT-LCNs developed presented some of the most desirable characteristics for mucosal delivery, that is, small particle size, positive surface charge, long-term stability, high EE, and mucoadhesion. In addition, they displayed two exciting features: First was their biodegradability by enzymes present in the mucus layer, such as lysozyme. This indicates a new Trojan-horse strategy which may enhance drug release in the proximity of the nasal mucosa. Second was their ability to enhance the nose-to-brain transport as evidenced by preliminary gamma scintigraphy studies.
This paper references
Pharm Res
(1994)
10.1016/J.BIOMATERIALS.2004.06.020
Involvement of protein kinase C in chitosan glutamate-mediated tight junction disruption.
J. Smith (2005)
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial
(2002)
10.1080/08982100600848769
Pros and Cons of the Liposome Platform in Cancer Drug Targeting
A. Gabizon (2006)
10.1111/j.1472-8206.2004.00299.x
Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update
M. Schachter (2005)
10.1016/j.ejpb.2008.10.009
Sodium hyaluronate as a mucoadhesive component in nasal formulation enhances delivery of molecules to brain tissue.
S. Horvát (2009)
10.1517/17425247.2015.1065812
Intranasal delivery: circumventing the iron curtain to treat neurological disorders
Yongjun Jiang (2015)
10.1007/s13346-012-0121-z
Current understanding of nasal morphology and physiology as a drug delivery target
J. Suman (2012)
10.1016/S0168-3659(02)00411-X
Mucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to rats.
H. Takeuchi (2003)
10.1016/j.jconrel.2014.06.053
Quantitative analysis of drug delivery to the brain via nasal route.
L. Kozlovskaya (2014)
10.1016/j.ijpharm.2013.05.040
Mucus as a barrier to lipophilic drugs.
H. Sigurdsson (2013)
10.3109/10717544.2014.920431
Nasal-nanotechnology: revolution for efficient therapeutics delivery
A. Kumar (2016)
10.1016/j.ijpharm.2009.06.019
Nanoparticles for direct nose-to-brain delivery of drugs.
Alpesh Mistry (2009)
10.1016/j.actbio.2011.07.025
Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies.
U. Seju (2011)
10.1211/0022357022539
Is nose‐to‐brain transport of drugs in man a reality?
L. Illum (2004)
10.1128/IAI.67.7.3267-3275.1999
Innate Antimicrobial Activity of Nasal Secretions
A. M. Cole (1999)
10.3109/03639045.2012.707210
Development of in vitro models to demonstrate the ability of PecSys®, an in situ nasal gelling technology, to reduce nasal run-off and drip
J. Castile (2013)
10.1023/A:1018967116988
Effect of Chitosan on the Permeability of Monolayers of Intestinal Epithelial Cells (Caco-2)
P. Artursson (2004)
10.1016/j.ijpharm.2015.06.021
Ex vivo permeation of tamoxifen and its 4-OH metabolite through rat intestine from lecithin/chitosan nanoparticles.
S. Barbieri (2015)
10.1080/10611860600721051
The brain targeting efficiency following nasally applied MPEG-PLA nanoparticles in rats
Q. Zhang (2006)
10.1016/j.jconrel.2014.05.003
Chitosan in nasal delivery systems for therapeutic drugs.
L. Casettari (2014)
10.1517/17425247.2011.588697
Chronic obstructive pulmonary disease: patho-physiology, current methods of treatment and the potential for simvastatin in disease management
L. Marín (2011)
10.1002/JPS.21031
Evaluation of human nasal RPMI 2650 cells grown at an air-liquid interface as a model for nasal drug transport studies.
Shuhua Bai (2008)
10.1016/j.ejps.2013.07.006
The effect of polymer coatings on physicochemical properties of spray-dried liposomes for nasal delivery of BSA.
K. Chen (2013)
MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals : a randomised placebo-controlled trial.
S. Feasson (2008)
10.1080/10611860903055470
Effect of physicochemical properties on intranasal nanoparticle transit into murine olfactory epithelium
Alpesh Mistry (2009)
10.1016/S0952-7915(00)00187-4
Antimicrobial peptides and proteins in the innate defense of the airway surface.
S. M. Travis (2001)
10.1186/1556-276X-8-102
Liposome: classification, preparation, and applications
A. Akbarzadeh (2013)
Drug Dev Ind Pharm
(2013)
10.1259/BJR/63780400
Monitoring rheumatoid arthritis synovitis with 99mTc-anti-CD3.
F. P. P. Martins (2008)
10.1016/j.colsurfb.2013.09.030
Optimization of curcumin nanoemulsion for intranasal delivery using design of experiment and its toxicity assessment.
Sumeet Sood (2014)
10.1016/j.expneurol.2010.04.006
Statins: Multiple neuroprotective mechanisms in neurodegenerative diseases
Q. Wang (2011)
10.1016/J.PHYSB.2006.06.034
Mean square hydrogen fluctuations in chitosan/lecithin nanoparticles from elastic neutron scattering experiments
F. Sonvico (2006)
10.1016/J.CHROMA.2005.12.031
Study on the conversion of three natural statins from lactone forms to their corresponding hydroxy acid forms and their determination in Pu-Erh tea.
D. Yang (2006)
10.1097/WAD.0b013e318157205b
Intranasal Mucoadhesive Microemulsion of Tacrine to Improve Brain Targeting
Viral V Jogani (2008)
10.2147/IJN.S35329
Development and evaluation of thymoquinone-encapsulated chitosan nanoparticles for nose-to-brain targeting: a pharmacoscintigraphic study
Sanjar Alam (2012)
10.1038/nrn2620
Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy
G. Bu (2009)
10.1517/17425247.5.10.1159
From nose to brain: understanding transport capacity and transport rate of drugs.
H. Wu (2008)
10.1007/s11051-013-2101-8
Interlaboratory comparison of size measurements on nanoparticles using nanoparticle tracking analysis (NTA)
P. Hole (2013)
10.1038/nn0403-345
Alzheimer's disease: the cholesterol connection
L. Puglielli (2003)
10.1046/J.1523-1755.2003.00744.X
Anti-inflammatory and immunomodulatory effects of statins.
L. Blanco-Colio (2003)
10.1093/rheumatology/kep471
Use of 99mTc-anti-CD3 scintigraphy in the differential diagnosis of rheumatic diseases.
F. L. Lopes (2010)
10.1016/j.accreview.2004.08.010
Trial of atorvastatin in rheumatoid arthritis (TARA): Double-blind, randomised placebo-controlled trial
D. McCarey (2004)
10.1016/j.jconrel.2012.03.020
Doxil®--the first FDA-approved nano-drug: lessons learned.
Y. Barenholz (2012)
10.1016/j.ijpharm.2010.08.020
Tight junction modulation by chitosan nanoparticles: comparison with chitosan solution.
D. Vllasaliu (2010)
10.2174/1568026614666140329232252
Expanding the therapeutic potential of statins by means of nanotechnology enabled drug delivery systems.
Bilquis Romana (2014)
10.1021/mp400154a
Determination of drug release kinetics from nanoparticles: overcoming pitfalls of the dynamic dialysis method.
Sweta Modi (2013)
10.1016/j.jconrel.2009.11.013
Lecithin/chitosan nanoparticles of clobetasol-17-propionate capable of accumulation in pig skin.
T. Şenyiğit (2010)
10.7326/0003-4819-137-3-200208060-00006
Apolipoprotein E 4 Allele, Elevated Midlife Total Cholesterol Level, and High Midlife Systolic Blood Pressure Are Independent Risk Factors for Late-Life Alzheimer Disease
M. Kivipelto (2002)
10.1016/j.colsurfb.2011.05.013
Characterisation of exosomes derived from human cells by nanoparticle tracking analysis and scanning electron microscopy.
V. Sokolova (2011)
10.1227/01.NEU.0000360130.52812.1D
EFFECT OF SIMVASTATIN ON GLIOMA CELL PROLIFERATION, MIGRATION, AND APOPTOSIS
Hongtao Wu (2009)
10.1016/S0928-0987(00)00087-7
Transport of drugs from the nasal cavity to the central nervous system.
L. Illum (2000)
10.18433/J3NC79
Intranasal drug delivery: how, why and what for?
A. Pires (2009)
10.1016/j.canlet.2012.08.031
Simvastatin inhibition of mevalonate pathway induces apoptosis in human breast cancer cells via activation of JNK/CHOP/DR5 signaling pathway.
Archana Gopalan (2013)
10.1016/S0169-409X(00)00118-6
Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future.
R. Mueller (2001)
10.1007/s11095-005-9397-8
Methods to Assess in Vitro Drug Release from Injectable Polymeric Particulate Systems
Susan Dsouza (2005)
Statin effects beyond lipid lowering — are they clinically relevant ?
P. O. Bonettia (2003)
10.1088/0953-8984/20/10/104211
Structure and organization of phospholipid/polysaccharide nanoparticles
Y. Gerelli (2008)
10.1016/j.addr.2011.11.002
Intranasal delivery of biologics to the central nervous system.
Jeffrey J Lochhead (2012)
10.1002/JPS.20283
Correlation between epithelial toxicity and surfactant structure as derived from the effects of polyethyleneoxide surfactants on caco-2 cell monolayers and pig nasal mucosa.
K. Ekelund (2005)
Use of 99 mTc - anti - CD 3 scintigraphy in the differential diagnosis of rheumatic diseases
FP Lopes (2010)
Carbohydr Polym
(1996)
10.1021/mp400735c
Brain uptake of a Zidovudine prodrug after nasal administration of solid lipid microparticles.
A. Dalpiaz (2014)
10.1016/j.expneurol.2006.03.019
High cholesterol content in neurons increases BACE, β-amyloid, and phosphorylated tau levels in rabbit hippocampus
O. Ghribi (2006)
10.1038/nrd1901
Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms
M. Jain (2005)
10.1016/j.jconrel.2013.02.009
Lecithin/chitosan controlled release nanopreparations of tamoxifen citrate: loading, enzyme-trigger release and cell uptake.
S. Barbieri (2013)
10.1007/S11883-000-0022-3
Pleiotropic effects of statins
J. Farmer (2000)
10.1016/J.TRANSPROCEED.2004.09.085
Preliminary results of [99mTc]OKT3 scintigraphy to evaluate acute rejection in renal transplants.
F. P. P. Martins (2004)
10.1016/0144-8617(96)00003-3
Degradation of partially N-acetylated chitosans with hen egg white and human lysozyme
Ragnhild J. Nordtveit (1996)
10.1016/j.ijpharm.2010.01.018
Preparation, characterization, and anticancer effects of simvastatin-tocotrienol lipid nanoparticles.
Hazem Ali (2010)
10.3109/03639045.2014.950271
Preparation and evaluation of SEDDS of simvastatin by in vivo, in vitro and ex vivo technique
Fahim Tamzeedul Karim (2015)
10.1161/01.ATV.0000038754.39483.CD
Unraveling pleiotropic effects of statins on plaque rupture.
W. Palinski (2002)
10.2147/ijn
科技期刊稿件处理的精细化管理——《International Journal of Nanomedicine〉〉投稿体会
鲁翠涛 (2014)
10.1007/s11095-010-0073-2
Critical Evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the Measurement of Nanoparticles and Protein Aggregates
V. Filipe (2010)
10.2174/1381612811306030510
Intranasal drug delivery to the central nervous system: present status and future outlook.
S. Tayebati (2013)
10.1016/J.JCONREL.2004.07.030
Transmucosal macromolecular drug delivery.
C. Prego (2005)
10.1016/J.CHEMPHYS.2007.08.006
Dynamics of lipid–saccharide nanoparticles by quasielastic neutron scattering
M. D. Bari (2008)
Chitosan based drug delivery systems
A. Piegat (2016)
Nanoencapsulated statins for brain delivery via nasal route
10.1007/978-1-61779-953-2_41
Nanoparticle tracking analysis for the multiparameter characterization and counting of nanoparticle suspensions.
M. Wright (2012)
10.1073/pnas.081620098
Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo
K. Fassbender (2001)
10.1002/JPS.20718
Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems?
L. Illum (2007)
10.1083/jcb.200207113
Amyloidogenic processing of the Alzheimer β-amyloid precursor protein depends on lipid rafts
R. Ehehalt (2003)
10.1023/A:1007594602449
Biovector™ Nanoparticles Improve Antinociceptive Efficacy of Nasal Morphine
D. Betbeder (2004)
10.1039/B916139B
Flexibility and drug release features of lipid/saccharide nanoparticles
Y. Gerelli (2010)



This paper is referenced by
10.1055/a-0586-8406
Preparation and Properties of 5-Fluorouracil-Loaded Chitosan Microspheres for the Intranasal Administration.
W. Li (2018)
10.1002/jcp.27932
Coenzyme Q10 protects against β‐cell toxicity induced by pravastatin treatment of hypercholesterolemia
estela Lorza-Gil (2019)
10.3390/ijms18010032
In Vivo Assessment of Clobetasol Propionate-Loaded Lecithin-Chitosan Nanoparticles for Skin Delivery
T. Şenyiğit (2016)
10.1016/j.jpba.2018.03.046
Development and validation of a RP‐HPLC method for the simultaneous detection and quantification of simvastatin's isoforms and coenzyme Q10 in lecithin/chitosan nanoparticles
A. Clementino (2018)
10.1080/14756366.2017.1378190
Neem oil nanoemulsions: characterisation and antioxidant activity
F. Rinaldi (2017)
10.1016/j.ijpharm.2020.119384
Intranasal tetrandrine temperature-sensitive in situ hydrogels for the treatment of microwave-induced brain injury.
L. Zhang (2020)
10.1016/J.JDDST.2019.04.005
Hydrophilic and hydrophobic polymeric benznidazole-loaded nanoparticles: Physicochemical properties and in vitro antitumor efficacy
A. M. D. S. Silva (2019)
10.1021/acs.molpharmaceut.7b00348
Gel-like TPGS-Based Microemulsions for Imiquimod Dermal Delivery: Role of Mesostructure on the Uptake and Distribution into the Skin.
I. Telò (2017)
10.1002/9781119749882.ch10
Bioadhesive Nanoformulations—Concepts and Preclinical Studies: A Critical Review
Monika Joshi (2020)
10.3390/ijms20092350
Self-Assembled Benznidazole-Loaded Cationic Nanoparticles Containing Cholesterol/Sialic Acid: Physicochemical Properties, In Vitro Drug Release and In Vitro Anticancer Efficacy
A. M. Dos Santos-Silva (2019)
10.2174/0929867326666190827151741
Intranasal Nanoparticulate Systems as Alternative Route of Drug Delivery.
Areen Alshweiat (2019)
10.3390/pharmaceutics11020086
Chitosan-Coated Nanoparticles: Effect of Chitosan Molecular Weight on Nasal Transmucosal Delivery
F. A. Bruinsmann (2019)
10.2147/IJN.S231477
Biomedical Applications of Multifunctional Polymeric Nanocarriers: A Review of Current Literature
Alicja Karabasz (2020)
10.1039/d0ra04890a
Preparation and characterisation of PHT-loaded chitosan lecithin nanoparticles for intranasal drug delivery to the brain
A. Yousfan (2020)
1 Surface-modified nanocarriers for nose-to-brain 2 delivery : from bioadhesion to targeting 3
F. Sonvico (2018)
10.18705/2311-4495-2017-4-1-63-69
EVALUATION OF CHITOSAN NANOPARTICLES BIODISTRIBUTION USING GROCOTT METHENAMINE SILVER STAINING
S. Zhuravskii (2017)
10.3390/pharmaceutics10010034
Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting
F. Sonvico (2018)
10.4155/tde-2017-0044
Drug delivery to the brain: how can nanoencapsulated statins be used in the clinic?
F. Sonvico (2017)
10.1016/j.jconrel.2018.12.007
inPentasomes: An innovative nose-to-brain pentamidine delivery blunts MPTP parkinsonism in mice.
F. Rinaldi (2019)
10.1016/j.ejpb.2020.06.003
Preparation and characterization of lamotrigine containing nanocapsules for nasal administration.
P. Gieszinger (2020)
10.1016/j.colsurfb.2019.110439
Novel O/W nanoemulsions for nasal administration: Structural hints in the selection of performing vehicles with enhanced mucopenetration.
Emanuela Di Cola (2019)
10.3390/pharmaceutics11020064
Formulation Strategies to Improve Nose-to-Brain Delivery of Donepezil
L. Espinoza (2019)
10.1016/j.phrs.2020.104795
Nose to brain drug delivery - a promising strategy for active components from herbal medicine for treating cerebral ischemia reperfusion.
Y. Long (2020)
10.1080/17425247.2019.1597051
Smart thermosensitive chitosan hydrogel for nasal delivery of ibuprofen to treat neurological disorders
H. Gholizadeh (2019)
10.1016/j.drudis.2018.01.005
An update on the role of nanovehicles in nose-to-brain drug delivery.
Y. Feng (2018)
10.1080/10717544.2020.1716878
Self-Assembled chitosan/phospholipid nanoparticles: from fundamentals to preparation for advanced drug delivery
Qingming Ma (2020)
Semantic Scholar Logo Some data provided by SemanticScholar